Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cardior Pharmaceuticals GmbH

www.cardior.de

Latest From Cardior Pharmaceuticals GmbH

New Mechanisms: Cardior’s Non-Coding RNA Therapeutic For Heart Failure

Germany’s Cardior is conducting clinical studies with an antisense oligonucleotide which inhibits a cellular microRNA believed to be involved in the pathology of heart failure, and is attracting attention from other pharma companies interested in the potential of this new mechanism of action.

Cardiovascular Clinical Trials

Finance Watch: VC Interest Lags At Early Stage – 'Hogwash' Or Evidence-Based?

Venture Capital Edition: A VC investor at a recent conference said it's "hogwash" that venture capitalists aren't interested in funding early-stage biopharma, but the trend toward large financings – such as the $220m raised to date by Rubius – and 2017 investment data suggest otherwise.

Financing Business Strategies

Venture Funding Deals: $65m For Iterum's Antibiotic; Genoa's IPF Drug Nets $62m

Iterum Therapeutics and Genoa Pharmaceuticals topped the list of biopharmaceutical start-up firms closing new venture capital rounds in May with $65m and $62m, respectively, to advance drug candidates for bacterial infections and idiopathic pulmonary fibrosis.

StartUps and SMEs Financing

Cardior Exploring MicroRNAs As Heart Failure Target

Emerging Company Profile: The German company Cardior has been set up to evaluate inhibitors of a microRNA in the treatment of heart failure, a condition that is poorly treated by current therapies.

Financing Research and Development Strategies
See All

Company Information

  • Industry
  • Biotechnology
    • Antisense, Oligonucleotides
  • In Vitro Diagnostics
  • Pharmaceuticals
  • Therapeutic Areas
  • Cardiovascular
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Germany
  • Company Type
  • Start-Up
  • Parent & Subsidiaries
  • Cardior Pharmaceuticals GmbH
  • Senior Management
  • Claudia Ulbrich, PhD, CEO
    Thomas Thum, CSO
  • Contact Info
  • Cardior Pharmaceuticals GmbH
    Phone: 0511-5325272
    Carl-Neuberg-Str.1
    Hannover, 30625
    Germany
UsernamePublicRestriction

Register